(0.22%) 5 111.09 points
(0.23%) 38 328 points
(0.19%) 15 959 points
(-1.37%) $82.70
(4.26%) $2.01
(-0.03%) $2 346.50
(-0.18%) $27.49
(3.68%) $956.00
(-0.16%) $0.933
(-0.24%) $11.00
(-0.45%) $0.797
(1.75%) $93.48
@ $3.72
发出时间: 15 Feb 2024 @ 00:00
回报率: -40.32%
上一信号: Feb 14 - 04:15
上一信号:
回报率: 1.36 %
Live Chart Being Loaded With Signals
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC)...
Stats | |
---|---|
今日成交量 | 53 226.00 |
平均成交量 | 726 238 |
市值 | 214.21M |
EPS | $0 ( 2024-03-14 ) |
下一个收益日期 | ( $-0.340 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.620 |
ATR14 | $0.00800 (0.36%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Rizvi Syed Ali-aamir | Buy | 250 000 | Employee Stock Option (Right to Buy) |
2024-04-01 | Rizvi Syed Ali-aamir | Buy | 185 000 | Common Stock |
2024-04-01 | Rizvi Syed Ali-aamir | Buy | 0 | |
2024-03-01 | Mylet Johanna | Buy | 80 743 | Common Stock |
2024-03-01 | Mylet Johanna | Sell | 18 091 | Common Stock |
INSIDER POWER |
---|
88.72 |
Last 92 transactions |
Buy: 9 056 534 | Sell: 550 582 |
音量 相关性
Poseida Therapeutics, 相关性
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Poseida Therapeutics, 相关性 - 货币/商品
Poseida Therapeutics, 财务报表
Annual | 2023 |
营收: | $64.70M |
毛利润: | $64.70M (100.00 %) |
EPS: | $-1.370 |
FY | 2023 |
营收: | $64.70M |
毛利润: | $64.70M (100.00 %) |
EPS: | $-1.370 |
FY | 2022 |
营收: | $130.36M |
毛利润: | $125.19M (96.03 %) |
EPS: | $-0.890 |
FY | 2021 |
营收: | $31 238.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.00201 |
Financial Reports:
No articles found.
Poseida Therapeutics,
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。